$TARS

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics, starting with eye care. Its marketed product, XDEMVY, is an eye drop approved in the U.S. for Demodex blepharitis. Tarsus sells XDEMVY through a commercial effort that includes a specialty sales force, digital and television campaigns, and education for eye care professionals. The company also shares clinical data on XDEMVY for patients with meibomian gland disease with eye care professionals. Tarsus is developing TP-04, a sterile ophthalmic gel formulation of lotilaner for potential treatment of ocular rosacea, and TP-05, an oral lotilaner tablet being studied for potential Lyme disease prevention. It also has a China licensing agreement for TP-03, the development code for lotilaner in Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals is headquartered in Irvine, California.

No enriched coverage for $TARS in the last 7 days.

—
$803K
Azamian Bobak R.
100%
See all $TARS insider activity →

TARS: Q3 growth and an expanding eye-care pipeline shape the 2027 outlook

Tarsus Pharmaceuticals reported 64% YoY growth in Q3, driven by direct-to-consumer sales, expanded field coverage, and broader patient reach. The company expects pipeline milestones for rosacea and Lyme data in H1 2027 and NORTHSTAR data in H2 2029, according to its Guggenheim Healthcare Innovation Conference transcript.

Tarsus Pharmaceuticals stock price target raised to $106 by H.C. Wainwright

H.C. Wainwright raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $106 from $88, citing strong sales of XDEMVY, its FDA-approved treatment for Demodex blepharitis. The company reported $194.6M in Q3 sales, up 64% YoY, but a wider-than-expected loss of $14.4 per share. Tarsus maintains a strong cash position and raised its sales outlook.

TARS sentiment & insider activity

Recent TARS coverage spans financial news, earnings and insider activity.

In the last 30 days, TARS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($803K). The most active reporter was Azamian Bobak R., President/CEO and Board Chair, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving TARS

AlphAI scores every news story that mentions TARS with an AI model for sentiment and relevance, and aggregates insider trades from Tarsus Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TARS

Score

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.

$TARSMedEarnings

Tarsus Reports Third Quarter 2026 Financial Results

Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tarsus Reports Third Quarter 2026 Financial Results Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales si

Tarsus Makes Neera Clase Permanent CCO

Tarsus Pharmaceuticals named Neera Clase as permanent CCO. Clase had been interim CCO since July. CEO Bobak Azamian cited her experience for the company's growth. TARS shares rose 1% to $71.51, with a market cap of $3.3 billion.

Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks

Oppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.

Related tickers